# Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

> **NCT06402708** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 172 (estimated)

## Conditions studied

- Thymic Carcinoma

## Interventions

- **DRUG:** Chemotherapy
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06402708
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-09
- **Primary completion:** 2027-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06402708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06402708, "Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06402708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*